USE OF A1CF INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
The present invention relates to an A1CF inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of A1CF inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules whi...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | WALTHER, Johanna Marie MUELLER-BRECKENRIDGE, Alan James HANSEN, Dennis Jul LUANGSAY, Souphalone PEDERSEN, Lykke |
| description | The present invention relates to an A1CF inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of A1CF inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to A1CF and capable of reducing the level of an A1 CF mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.
La présente invention concerne un inhibiteur de A1CF destiné à être utilisé dans le traitement d'une infection par le VHB, en particulier une infection chronique par le VHB. L'invention concerne en particulier l'utilisation d'inhibiteurs de A1CF pour déstabiliser l'ADNccc, tel que l'ADNccc du VHB. L'invention concerne également des molécules d'acide nucléique qui sont complémentaires de A1CF et capables de réduire le taux d'un ARNm de A1CF. La présente invention concerne également une composition pharmaceutique et son utilisation dans le traitement d'une infection par le VHB. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2022038211A3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2022038211A3</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2022038211A33</originalsourceid><addsrcrecordid>eNrjZLAPDXZV8HdTcDR0dlPw9PPwdPIM8Q8KVnDzD1IICXJ1DPH0c1fwcA0AMkI8gxWcFMI8g0KDgSrdXJ1DPP39eBhY0xJzilN5oTQ3g7Kba4izh25qQX58anFBYnJqXmpJfLi_kYGRkYGxhZGhoaOxMXGqAAW9KwY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>USE OF A1CF INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION</title><source>esp@cenet</source><creator>WALTHER, Johanna Marie ; MUELLER-BRECKENRIDGE, Alan James ; HANSEN, Dennis Jul ; LUANGSAY, Souphalone ; PEDERSEN, Lykke</creator><creatorcontrib>WALTHER, Johanna Marie ; MUELLER-BRECKENRIDGE, Alan James ; HANSEN, Dennis Jul ; LUANGSAY, Souphalone ; PEDERSEN, Lykke</creatorcontrib><description>The present invention relates to an A1CF inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of A1CF inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to A1CF and capable of reducing the level of an A1 CF mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.
La présente invention concerne un inhibiteur de A1CF destiné à être utilisé dans le traitement d'une infection par le VHB, en particulier une infection chronique par le VHB. L'invention concerne en particulier l'utilisation d'inhibiteurs de A1CF pour déstabiliser l'ADNccc, tel que l'ADNccc du VHB. L'invention concerne également des molécules d'acide nucléique qui sont complémentaires de A1CF et capables de réduire le taux d'un ARNm de A1CF. La présente invention concerne également une composition pharmaceutique et son utilisation dans le traitement d'une infection par le VHB.</description><language>eng ; fre</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220428&DB=EPODOC&CC=WO&NR=2022038211A3$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220428&DB=EPODOC&CC=WO&NR=2022038211A3$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>WALTHER, Johanna Marie</creatorcontrib><creatorcontrib>MUELLER-BRECKENRIDGE, Alan James</creatorcontrib><creatorcontrib>HANSEN, Dennis Jul</creatorcontrib><creatorcontrib>LUANGSAY, Souphalone</creatorcontrib><creatorcontrib>PEDERSEN, Lykke</creatorcontrib><title>USE OF A1CF INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION</title><description>The present invention relates to an A1CF inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of A1CF inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to A1CF and capable of reducing the level of an A1 CF mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.
La présente invention concerne un inhibiteur de A1CF destiné à être utilisé dans le traitement d'une infection par le VHB, en particulier une infection chronique par le VHB. L'invention concerne en particulier l'utilisation d'inhibiteurs de A1CF pour déstabiliser l'ADNccc, tel que l'ADNccc du VHB. L'invention concerne également des molécules d'acide nucléique qui sont complémentaires de A1CF et capables de réduire le taux d'un ARNm de A1CF. La présente invention concerne également une composition pharmaceutique et son utilisation dans le traitement d'une infection par le VHB.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLAPDXZV8HdTcDR0dlPw9PPwdPIM8Q8KVnDzD1IICXJ1DPH0c1fwcA0AMkI8gxWcFMI8g0KDgSrdXJ1DPP39eBhY0xJzilN5oTQ3g7Kba4izh25qQX58anFBYnJqXmpJfLi_kYGRkYGxhZGhoaOxMXGqAAW9KwY</recordid><startdate>20220428</startdate><enddate>20220428</enddate><creator>WALTHER, Johanna Marie</creator><creator>MUELLER-BRECKENRIDGE, Alan James</creator><creator>HANSEN, Dennis Jul</creator><creator>LUANGSAY, Souphalone</creator><creator>PEDERSEN, Lykke</creator><scope>EVB</scope></search><sort><creationdate>20220428</creationdate><title>USE OF A1CF INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION</title><author>WALTHER, Johanna Marie ; MUELLER-BRECKENRIDGE, Alan James ; HANSEN, Dennis Jul ; LUANGSAY, Souphalone ; PEDERSEN, Lykke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2022038211A33</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2022</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>WALTHER, Johanna Marie</creatorcontrib><creatorcontrib>MUELLER-BRECKENRIDGE, Alan James</creatorcontrib><creatorcontrib>HANSEN, Dennis Jul</creatorcontrib><creatorcontrib>LUANGSAY, Souphalone</creatorcontrib><creatorcontrib>PEDERSEN, Lykke</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>WALTHER, Johanna Marie</au><au>MUELLER-BRECKENRIDGE, Alan James</au><au>HANSEN, Dennis Jul</au><au>LUANGSAY, Souphalone</au><au>PEDERSEN, Lykke</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>USE OF A1CF INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION</title><date>2022-04-28</date><risdate>2022</risdate><abstract>The present invention relates to an A1CF inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of A1CF inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules which are complementary to A1CF and capable of reducing the level of an A1 CF mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a HBV infection.
La présente invention concerne un inhibiteur de A1CF destiné à être utilisé dans le traitement d'une infection par le VHB, en particulier une infection chronique par le VHB. L'invention concerne en particulier l'utilisation d'inhibiteurs de A1CF pour déstabiliser l'ADNccc, tel que l'ADNccc du VHB. L'invention concerne également des molécules d'acide nucléique qui sont complémentaires de A1CF et capables de réduire le taux d'un ARNm de A1CF. La présente invention concerne également une composition pharmaceutique et son utilisation dans le traitement d'une infection par le VHB.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2022038211A3 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE |
| title | USE OF A1CF INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T16%3A08%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=WALTHER,%20Johanna%20Marie&rft.date=2022-04-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2022038211A3%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |